Waldencast's Q1 2025 results showed a 4.1% year-over-year revenue decline, with net loss expanding significantly to $20.7 million. Despite the revenue headwinds, the company maintained strong gross margins and continued investing in marketing to support future growth.

Waldencast achieved net revenue of $72.1 million in Q4 2024, reflecting a 30.8% increase compared to Q4 2023. The company reported a net loss of $22.6 million, driven by operational investments and non-recurring costs, while Adjusted EBITDA doubled year-over-year to $11.2 million. Both Obagi Medical and Milk Makeup delivered strong growth and margin improvements.